{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T17:01:28Z","timestamp":1775840488280,"version":"3.50.1"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,10,14]],"date-time":"2022-10-14T00:00:00Z","timestamp":1665705600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,10,14]],"date-time":"2022-10-14T00:00:00Z","timestamp":1665705600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hypertens Res"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1038\/s41440-022-01015-x","type":"journal-article","created":{"date-parts":[[2022,10,14]],"date-time":"2022-10-14T01:02:49Z","timestamp":1665709369000},"page":"119-127","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Fatty liver index and cardiovascular outcomes in never-treated hypertensive patients: a prospective cohort"],"prefix":"10.1038","volume":"46","author":[{"given":"Eirini","family":"Siafi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ioannis","family":"Andrikou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Costas","family":"Thomopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dimitrios","family":"Konstantinidis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niki","family":"Kakouri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fotis","family":"Tatakis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Kariori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina","family":"Filippou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ioannis","family":"Zamanis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eleni","family":"Manta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sotirios","family":"Drogkaris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ioannis","family":"Liatakis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dimitrios","family":"Polyzos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Costas","family":"Tsioufis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,10,14]]},"reference":[{"key":"1015_CR1","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.1002\/hep.29845","volume":"67","author":"XJ Zhang","year":"2018","unstructured":"Zhang XJ, She ZG, Li H. Time to step-up the fight against NAFLD. Hepatology 2018;67:2068\u201371.","journal-title":"Hepatology"},{"key":"1015_CR2","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1002\/hep.30702","volume":"70","author":"F Zhou","year":"2019","unstructured":"Zhou F, Zhou J, Wang W, Zhang XJ, Ji YX, Zhang P, et al. Unexpected rapid increase in the burden of nonalcoholic fatty liver disease in China from 2008 to 2018: a systematic review and metaanalysis. Hepatology 2019;70:1119\u201333.","journal-title":"Hepatology"},{"key":"1015_CR3","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1097\/MEG.0000000000001191","volume":"30","author":"D Oikonomou","year":"2018","unstructured":"Oikonomou D, Georgiopoulos G, Katsi V, Kourek C, Tsioufis C, Alexopoulou A, et al. Non-alcoholic fatty liver disease and hypertension: coprevalent or correlated? Eur J Gastroenterol Hepatol. 2018;30:979\u201385.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"1015_CR4","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1097\/HJH.0000000000001204","volume":"35","author":"F Bonnet","year":"2017","unstructured":"Bonnet F, Gastaldelli A, Pihan-Le Bars F, Natali A, Roussel R, Petrie J, et al. D.E.S.I.R., RISC Study Groups. Gamma-glutamyltransferase, fatty liver index and hepatic insulin resistance are associated with incident hypertension in two longitudinal studies. J Hypertens. 2017;35:493\u2013500.","journal-title":"J Hypertens"},{"key":"1015_CR5","doi-asserted-by":"publisher","first-page":"e0143560","DOI":"10.1371\/journal.pone.0143560","volume":"10","author":"JH Huh","year":"2015","unstructured":"Huh JH, Ahn SV, Koh SB, Choi E, Kim JY, Sung KC, et al. A Prospective Study of fatty liver index and incident hypertension: the KoGES-ARIRANG Study. PLoS One. 2015;10:e0143560.","journal-title":"PLoS One"},{"key":"1015_CR6","doi-asserted-by":"crossref","first-page":"e168","DOI":"10.1161\/ATV.0000000000000153","volume":"42","author":"PB Duell","year":"2022","unstructured":"Duell PB, Welty FK, Miller M, Chait A, Hammond G, Ahmad Z, et al. American Heart Association Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Hypertension; Council on the Kidney in Cardiovascular Disease; Council on Lifestyle and Cardiometabolic Health; and Council on Peripheral Vascular Disease. Nonalcoholic fatty liver disease and cardiovascular risk: a scientific statement from the American Heart Association. Arterioscler Thromb Vasc Biol. 2022;42:e168\u2013e185.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"1015_CR7","first-page":"6","volume":"2","author":"G Bedogni","year":"2006","unstructured":"Bedogni G, Bellentani S, Miglioli L, Masutti F, Passalacqua M, Castiglione A, et al. The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol. 2006;2:6\u201333.","journal-title":"BMC Gastroenterol"},{"key":"1015_CR8","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1161\/CIRCRESAHA.119.316337","volume":"126","author":"J Cai","year":"2020","unstructured":"Cai J, Zhang XJ, Ji YX, Zhang P, She ZG, Li H. Nonalcoholic fatty liver disease pandemic fuels the upsurge in cardiovascular diseases. Circ Res. 2020;126:679\u2013704.","journal-title":"Circ Res"},{"key":"1015_CR9","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1097\/HJH.0000000000001940","volume":"36","author":"B Williams","year":"2018","unstructured":"Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. Authors\/Task Force Members:. 2018 ESC\/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. J Hypertens. 2018;36:1953\u20132041.","journal-title":"J Hypertens"},{"key":"1015_CR10","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1097\/HJH.0b013e328363e964","volume":"31","author":"E O\u2019Brien","year":"2013","unstructured":"O\u2019Brien E, Parati G, Stergiou G, Asmar R, Beilin L, Bilo G, et al. European Society of Hypertension Working Group on Blood Pressure Monitoring. European Society of Hypertension position paper on ambulatory blood pressure monitoring. J Hypertens. 2013;31:1731\u201368.","journal-title":"J Hypertens"},{"key":"1015_CR11","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1159\/000100489","volume":"105","author":"CM Clase","year":"2007","unstructured":"Clase CM, Kiberd BA, Garg AX. Relationship between glomerular filtration rate and the prevalence of metabolic abnormalities: results from the Third National Health and Nutrition Examination Survey (NHANES III). Nephron Clin Pr. 2007;105:178\u201384.","journal-title":"Nephron Clin Pr"},{"key":"1015_CR12","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1161\/circ.106.25.3143","volume":"106","author":"Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III","year":"2002","unstructured":"Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Final report. Circulation 2002;106:3143\u2013421.","journal-title":"Circulation"},{"key":"1015_CR13","doi-asserted-by":"publisher","first-page":"3153","DOI":"10.1016\/j.jacc.2018.11.005","volume":"73","author":"DM Lloyd-Jones","year":"2019","unstructured":"Lloyd-Jones DM, Braun LT, Ndumele CE, Smith SC Jr, Sperling LS, Virani SM, et al. Use of risk assessment tools to guide decision making in the primary prevention of atherosclerotic cardiovascular disease: a special report from the American Heart Association and American College of Cardiology. J Am Coll Cardiol. 2019;73:3153\u201367.","journal-title":"J Am Coll Cardiol"},{"key":"1015_CR14","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1097\/HJH.0000000000002123","volume":"37","author":"C Thomopoulos","year":"2019","unstructured":"Thomopoulos C, Antza C. Legacy effect on mortality in antihypertensive drug comparison trials: a meta-analysis. J Hypertens. 2019;37:1532\u20134.","journal-title":"J Hypertens"},{"key":"1015_CR15","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1097\/HJH.0000000000001233","volume":"35","author":"Y Hirakawa","year":"2017","unstructured":"Hirakawa Y, Arima H, Rodgers A, Woodward M, Chalmers J. Cumulative in-trial and posttrial effects of blood pressure and lipid lowering: systematic review and meta-analysis. J Hypertens. 2017;35:905\u201313.","journal-title":"J Hypertens"},{"key":"1015_CR16","doi-asserted-by":"publisher","first-page":"3313","DOI":"10.1007\/s00018-018-2860-6","volume":"75","author":"DH Ipsen","year":"2018","unstructured":"Ipsen DH, Lykkesfeldt J, Tveden-Nyborg P. Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease. Cell Mol Life Sci. 2018;75:3313\u20137.","journal-title":"Cell Mol Life Sci"},{"key":"1015_CR17","doi-asserted-by":"publisher","first-page":"204201881987730","DOI":"10.1177\/2042018819877300","volume":"10","author":"YL Lan","year":"2019","unstructured":"Lan YL, Lou JC, Lyu W, Zhang B. Update on the synergistic effect of HSL and insulin in the treatment of metabolic disorders. Ther Adv Endocrinol Metab. 2019;10:2042018819877300.","journal-title":"Ther Adv Endocrinol Metab"},{"key":"1015_CR18","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s13098-020-00570-y","volume":"12","author":"AF Godoy-Matos","year":"2020","unstructured":"Godoy-Matos AF, Silva Junior WS, Valerio CM. NAFLD as a continuum: from obesity to metabolic syndrome and diabetes. Diabetol Metab Syndr. 2020;12:60.","journal-title":"Diabetol Metab Syndr"},{"key":"1015_CR19","doi-asserted-by":"publisher","first-page":"2470","DOI":"10.1097\/HJH.0000000000002954","volume":"39","author":"E Siafi","year":"2021","unstructured":"Siafi E, Andrikou I, Konstantinidis D, Kakouri N, Iliakis P, Koskinas J, et al. Fatty liver index and hypertension-mediated organ damage in never-treated hypertensive patients without diabetes mellitus. J Hypertens. 2021;39:2470\u20137.","journal-title":"J Hypertens"},{"key":"1015_CR20","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1038\/hr.2009.74","volume":"32","author":"M Iwai","year":"2009","unstructured":"Iwai M, Horiuchi M. Devil and angel in the renin-angiotensin system: ACE angiotensin II-AT1 receptor axis vs. ACE2-angiotensin-(1-7)-mas receptor axis. Hypertens Res. 2009;32:533\u20136.","journal-title":"Hypertens Res"},{"key":"1015_CR21","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.tem.2005.02.003","volume":"16","author":"G Giacchetti","year":"2005","unstructured":"Giacchetti G, Sechi LA, Rilli S, Carey RM. The renin-angiotensin aldosterone system, glucose metabolism and diabetes. Trends Endocrinol Metab. 2005;16:120\u20136.","journal-title":"Trends Endocrinol Metab"}],"container-title":["Hypertension Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41440-022-01015-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41440-022-01015-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41440-022-01015-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T00:08:11Z","timestamp":1672877291000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41440-022-01015-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,14]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["1015"],"URL":"https:\/\/doi.org\/10.1038\/s41440-022-01015-x","relation":{},"ISSN":["0916-9636","1348-4214"],"issn-type":[{"value":"0916-9636","type":"print"},{"value":"1348-4214","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,14]]},"assertion":[{"value":"12 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"CTh reports honoraria for lectures or consultancy fees from Menarini, Medtronic, Berlin-Chemie, Sanofi, and AstraZeneca. CTs, reports honoraria for advisory boards and lectures from Medtronic, Servier, Bayer, Menarini, Novartis, AstraZeneca, Boehringer, Pfizer, Pythagoras, Sanofi, and Amgen. All other authors report no conflict. However, all authors have not received any funding directly related to the subject or content of this work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}